Latest Us Market News

IRIS Metals has successfully completed test mining at its fully permitted Beecher lithium project and expanded its US footprint with a strategic acquisition, while securing $4.27 million to fund ongoing exploration and development.

Optiscan Imaging Ltd has launched its first in-human breast cancer study and unveiled a new veterinary imaging device, while securing a key US collaboration to support FDA submissions.

Pure Hydrogen reports a second consecutive quarter of positive cash flow, expands its international hydrogen vehicle footprint, and secures a 15-year gas project permit in Queensland.

Tasman Resources progresses exploration at Lake Torrens and Parkinson Dam projects while managing capital through a recent entitlement offer and loan repayments.

Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.

Eden Innovations reports a striking 114% year-on-year jump in Q4 US sales of its EdenCrete® products, alongside a 50% annual sales increase and significant debt reduction plans.

Cettire warns that recent US tariff changes removing duty-free exemptions on shipments under $800 could impact nearly half its revenue. The luxury e-commerce platform is evaluating the consequences and adjusting its global strategy.

Airtasker Limited has reported its second consecutive year of positive free cash flow alongside robust revenue growth, fueling accelerated expansion in the UK and US marketplaces.

MedAdvisor Solutions reported a 16.6% revenue decline in 4Q FY25, driven by US market challenges, while completing the sale of its ANZ business and initiating a strategic review of its US operations.

Airtasker Limited reports its second consecutive year of positive free cash flow alongside a 29% jump in marketplaces revenue, driven by explosive growth in the UK and US markets.

MedAdvisor reports a significant revenue decline in FY25 amid US program delays but strengthens its balance sheet through a capital raise and ANZ business sale. The company signals a strategic pivot with potential US business divestment on the horizon.

EVE Health Group has completed its acquisition of Nextract, raised $1 million to fund manufacturing, and achieved key regulatory and commercial milestones for its pharmaceutical products targeting erectile dysfunction and dysmenorrhea.